Insider Selling: Cerus (NASDAQ:CERS) COO Sells 165,200 Shares of Stock

by · The Markets Daily

Cerus Corporation (NASDAQ:CERS – Get Free Report) COO Vivek Jayaraman sold 165,200 shares of the company’s stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $1.66, for a total value of $274,232.00. Following the completion of the transaction, the chief operating officer directly owned 1,747,674 shares in the company, valued at $2,901,138.84. The trade was a 8.64% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Cerus Stock Performance

NASDAQ CERS traded up $0.11 on Monday, reaching $1.80. The stock had a trading volume of 1,334,517 shares, compared to its average volume of 2,144,514. Cerus Corporation has a 1-year low of $1.12 and a 1-year high of $2.96. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.73 and a quick ratio of 1.17. The company has a market cap of $345.91 million, a P/E ratio of -22.50 and a beta of 1.51. The firm has a fifty day moving average of $2.29 and a two-hundred day moving average of $1.87.

Cerus (NASDAQ:CERS – Get Free Report) last released its quarterly earnings results on Monday, March 2nd. The biotechnology company reported ($0.01) EPS for the quarter, hitting analysts’ consensus estimates of ($0.01). Cerus had a negative net margin of 7.58% and a negative return on equity of 26.09%. The business had revenue of $64.58 million for the quarter, compared to analyst estimates of $59.31 million. On average, equities research analysts anticipate that Cerus Corporation will post -0.08 EPS for the current year.

Institutional Investors Weigh In On Cerus

A number of large investors have recently modified their holdings of CERS. Cubist Systematic Strategies LLC lifted its position in shares of Cerus by 152.4% during the 1st quarter. Cubist Systematic Strategies LLC now owns 104,101 shares of the biotechnology company’s stock worth $145,000 after buying an additional 62,854 shares during the last quarter. AQR Capital Management LLC grew its holdings in shares of Cerus by 291.6% during the 1st quarter. AQR Capital Management LLC now owns 1,429,062 shares of the biotechnology company’s stock valued at $1,986,000 after purchasing an additional 1,064,133 shares during the last quarter. Millennium Management LLC increased its position in Cerus by 12.0% during the 1st quarter. Millennium Management LLC now owns 3,222,327 shares of the biotechnology company’s stock worth $4,479,000 after purchasing an additional 344,395 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in Cerus in the first quarter valued at approximately $32,000. Finally, Savant Capital LLC increased its holdings in shares of Cerus by 339.6% during the second quarter. Savant Capital LLC now owns 94,812 shares of the biotechnology company’s stock worth $134,000 after buying an additional 73,244 shares in the last quarter. Institutional investors and hedge funds own 78.37% of the company’s stock.

Wall Street Analyst Weigh In

CERS has been the subject of a number of recent analyst reports. TD Cowen reiterated a “buy” rating on shares of Cerus in a research report on Monday, January 12th. Wall Street Zen cut Cerus from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Finally, Zacks Research downgraded Cerus from a “hold” rating to a “strong sell” rating in a research note on Thursday. One investment analyst has rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Reduce”.

View Our Latest Analysis on CERS

About Cerus

(Get Free Report)

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.

See Also